| 1/4 | US=47 / Câncer Yap TA, Molife LR, Bono JS. CDK inhibitors as anticancer agents. In: Dai W. Checkpoint responses in cancer therapy. New Jersey: Humana Press, 2008. p. 135-62. (Cancer Drug Discovery and Development) ISBN 978-1-58829-930-7. INIBIDORES DE CDK; AGENTES ANTICANCERIGENOS; CICLO CELULAR; CICLINA DEPENDENTE DE QUINASE; CICLINA; INIBIDOR; FLAVOPIRIDOL; UCN-01; E7070; SELICICLIB; BMS 387032; ZD 304709 |
| 2/4 | US=67 / Biol/Mol Knights CD, Pestell RG. The cell cycle: therapeutic targeting of cell regulatory components and effector pathways in cancer. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 3-32. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. CICLO CELULAR; SEGMENTACAO TERAPEUTICA; COMPONENTES CELULARES; VIAS REGULADORAS; CANCER; CICLINA DEPENDENTE DE QUINASE; INIBIDORES CDK; TERAPIA; ACETILACAO; P53; CICLINA D1; EGFR; HDAC; STI-571; FLAVOPIRIDOL; INIBIDOR CDK2 |
| 3/4 | US=58 / Câncer Siddik ZH. Targeting p21-dependent pathways for cell death in cancer therapy. In: ___. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 199-213. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6. DANOS NO DNA; P21; CICLINA DEPENDENTE DE QUINASE; G1 RESPOSTA CHECKPOINT; PARADA DO CICLO CELULAR; TRANSATIVACAO; PARADA DO CICLO GENE |
| 4/4 | US=58 / Câncer Pevarello P, Bischoff JR, Mercurio C. Targeting cyclin-dependent kinases with small molecular inhibitors. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 235-44. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6. CICLINA DEPENDENTE DE QUINASE; INIBIDOR DE MOLECULA PEQUENA; SELETIVIDADE; DE MULTI-ALVO; ENSAIOS CLINICOS |